Molecular Partners AG (STU:6ML) FFO per Share


STU:6ML Molecular Partners AG STU:6ML
31 GF Score
Price €3.36
GF Value €0.40
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG FFO per Share?

FFO per Share only applies to REITs.

STU:6ML
31GF Score
Molecular Partners AG STU:6ML
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (STU:6ML) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of €3.36 is trading 740% above its estimated GF Value™ of €0.40. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for STU:6ML:

  • FFO per Share:
  • GF Value™: €0.40 vs. price of €3.36 (740% above fair value)
  • GF Score™: 31/100 with 3 warning signs

No single metric tells the full story. See the STU:6ML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
31GF Score

Get the complete analysis for STU:6ML

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.36
Price
€0.40
GF Value